Locally Advance Lung Cancer - 17 Dec 2022
Twice daily tRT by IMRT compasred with SIB IRT with concurrent chemotherapy
Long term Survival & Competing Rsks of Death in the ESPATUE Randomized Phase III
Impact of radiation dose to the immune cells in unresectable or stage III
Exposure of the heart in lung cancer radiation therapy A Systematic review
Panel Discussion - Local Therapy Locally Advanced
Nivolumab + Chemotherapy Vs Chemotherapy as NAT in Resectable Stage III
Overall survival & Biomarker analysis of Neoadjuvant Nivolumab Plus Chemotherapy
Pre treatment ctDNA Levels Significantly Predicts of OS & PFS in NADIM II Trial
Sugemalimab vs Placebo after cCRT or sCRT in Patients with Unresectable stage III
Consolidation nivolumab plus ipilimumab or nivolumab alone following
Proton therapy & concurrent Chemotherapy in stage III NSCLC
Concurrent versus sequential immune checkpoint inhibition in stage III NSCLC
Impact of grade 2 Pneumonitis on Patient Reported outcomes with Durvalumab
Association of Driver Oncogene Variations with Outcomes in Patients
Panel Discussion - Durvalumab in Stage III NSCLC